Reports Q4 revenue $80,000, consensus $31,700. Michael Weiss, the Company’s Chairman and Chief Executive Officer, stated, "2022 was a pivotal year for TG with the approval of BRIUMVI for relapsing forms of Multiple Sclerosis, and 2023 is off to an exciting start with the commercial launch of BRIUMVI. Our teams are hard at work introducing BRIUMVI to the MS community and while we are only 4 weeks into the launch, we are encouraged by the early feedback from providers, payors and advocates." Weiss continued, "Our highest priority is our commitment to patients and to ensure that patients who want BRIUMVI will have access to BRIUMVI. We look forward to building on the foundation we are developing in this early launch phase and extending it throughout 2023 and beyond."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on TGTX:
- TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial Results
- TG Therapeutics options imply 4.1% move in share price post-earnings
- TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2022 Financial Results and Business Update
- TG Therapeutics Announces Presentation of Data from the ULTIMATE I & II Phase 3 Trials of BRIUMVI™ (ublituximab-xiiy) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
- TG Therapeutics call volume above normal and directionally bullish
